Personalized oncology: genomic screening in phase 1

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Acta Pathologica, Microbiologica et Immunologica Scandinavica (APMIS)

• Publication date

  2014-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/apm.12293PMID 25046202
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.

  2014cited by this paper
• Ceritinib in ALK-rearranged non-small-cell lung cancer.

  2014cited by this paper
• Molecular diagnostics

  2014cited by this paper
• Ceritinib in ALK-rearranged non-small-cell lung cancer.

  2014cited by this paper
• Traditional Roles in a Non-Traditional Setting: Genetic Counseling in Precision Oncology

  2014cited by this paper
• Liquid biopsies: genotyping circulating tumor DNA.

  2014cited by this paper
• Dabrafenib and Trametinib, Alone and in Combination for BRAF-Mutant Metastatic Melanoma

  2014cited by this paper
• Cancer Genome Landscapes

  2013cited by this paper
• Activating ESR1 mutations in hormone-resistant metastatic breast cancer

  2013cited by this paper
• L04.04 * Winther: a study to select rational therapeutics based on the analysis of tumor and matched normal tissue biopsies in subjects with advanced malignancies

  2013cited by this paper
• Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer.

  2013cited by this paper
• Analysis of circulating tumor DNA to monitor metastatic breast cancer.

  2013influential reference
• Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

  2013cited by this paper
• Molecular screening for cancer treatment optimization: MOSCATO 01 - A prospective molecular triage trial, interim results

  2013cited by this paper
• Genomic medicine frontier in human solid tumors: prospects and challenges.

  2013cited by this paper
• Next-generation sequencing reveals high concordance of recurrent somatic alterations between primary tumor and metastases from patients with non-small-cell lung cancer.

  2013cited by this paper
• Feasibility of real time next generation sequencing of cancer genes linked to drug response: Results from a clinical trial

  2013cited by this paper
• Real-time liquid biopsy in cancer patients: fact or fiction?

  2013cited by this paper
• Circumventing cancer drug resistance in the era of personalized medicine.

  2012cited by this paper
• Intratumor Heterogeneity: Seeing the Wood for the Trees

  2012cited by this paper
• The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers

  2012cited by this paper
• Systematic identification of genomic markers of drug sensitivity in cancer cells

  2012cited by this paper
• Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.

  2012cited by this paper
• The clonal and mutational evolution spectrum of primary triple-negative breast cancers

  2012cited by this paper
• The genetic basis for cancer treatment decisions.

  2012cited by this paper
• Genome Sequencing Identifies a Basis for Everolimus Sensitivity

  2012cited by this paper
• Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials.

  2012cited by this paper
• Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative

  2012cited by this paper
• Outcomes of research biopsies in phase I clinical trials: the MD anderson cancer center experience.

  2011cited by this paper
• Personalized Oncology Through Integrative High-Throughput Sequencing: A Pilot Study

  2011cited by this paper
• Hallmarks of cancer: the next generation.

  2011cited by this paper
• Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

  2011cited by this paper
• KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients

  2011cited by this paper
• Reasons given by patients for participating, or not, in Phase 1 cancer trials.

  2011cited by this paper
• Inhibition of mutated, activated BRAF in metastatic melanoma.

  2010cited by this paper
• PIK3CA Mutations May Be Discordant between Primary and Corresponding Metastatic Disease in Breast Cancer

  2010cited by this paper
• F1000 highlights

  2010cited by this paper
• Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

  2010cited by this paper
• Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers.

  2010cited by this paper
• Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.

  2010cited by this paper
• Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.

  2010cited by this paper
• Proof of concept review Lapatinib : the evidence for its therapeutic value in metastatic breast cancer

  2009cited by this paper
• Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis

  2009cited by this paper
• Significance of Circulating Tumor Cells Detected by the CellSearch System in Patients with Metastatic Breast Colorectal and Prostate Cancer

  2009cited by this paper
• Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.

  2009cited by this paper
• The cancer genome

  2009cited by this paper
• New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

  2009influential reference
• Melanoma biology and new targeted therapy

  2007cited by this paper
• Pathobiology of ALK+ anaplastic large-cell lymphoma.

  2007cited by this paper
• Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer

  2007cited by this paper
• Lapatinib: the evidence for its therapeutic value in metastatic breast cancer

  2005cited by this paper
• Anticancer drugs: To the rescue?

  2004cited by this paper
• Cancer genes and the pathways they control

  2004cited by this paper
• Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

  2004cited by this paper
• Mutations of the BRAF gene in human cancer

  2002cited by this paper
• Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

  2001cited by this paper
• The n e w e n g l a n d j o u r n a l of m e d i c i n e

  2001cited by this paper
• Phase II clinical trial design for noncytotoxic anticancer agents for which time to disease progression is the primary endpoint.

  2000cited by this paper
• Amplification of a novel v-erbB-related gene in a human mammary carcinoma.

  1985cited by this paper

• Neoepitope load, T cell signatures and PD-L2 as combined biomarker strategy for response to checkpoint inhibition immunotherapy

  2023cites this paper
• New pathogenic germline variants identified in mesothelioma.

  2023cites this paper
• Extensive genomic analysis in patients with KRAS-mutated solid tumors shows high frequencies of concurrent alterations and potential targets but has limited clinical impact

  2022cites this paper
• Application of cell-free DNA for genomic tumor profiling: a feasibility study

  2019cites this paper
• High frequency of pathogenic germline variants within homologous recombination repair in patients with advanced cancer

  2019cites this paper
• Global trends in the distribution of cancer types among patients in oncology phase I trials, 1991–2015

  2018cites this paper
• Circulating tumor DNA as a marker of treatment response in BRAF V600E mutated non-melanoma solid tumors

  2018cites this paper
• Copenhagen Prospective Personalized Oncology (CoPPO)—Clinical Utility of Using Molecular Profiling to Select Patients to Phase I Trials

  2018cites this paper
• The Molecular Profiling Lottery: More Accuracy, Less Precision, and No Cost

  2018cites this paper
• Fast renal decline to end-stage renal disease: an unrecognized feature of nephropathy in diabetes.

  2017cites this paper
• Detection of copy number alterations in cell-free tumor DNA from plasma

  2017cites this paper
• Clinical Outcome of Patients with Advanced Biliary Tract Cancer in a Dedicated Phase I Unit.

  2017cites this paper
• Concordance of Mutation Detection in Circulating Tumor DNA in Early Clinical Trials Using Different Blood Collection Protocols.

  2017cites this paper
• Improving gastric cancer preclinical studies using diverse in vitro and in vivo model systems

  2016cites this paper
• The changing landscape of phase I trials in oncology

  2016cites this paper
• Multicenter Evaluation of a Novel Automated Rapid Detection System of BRAF Status in Formalin-Fixed, Paraffin-Embedded Tissues.

  2016cites this paper
• Elucidation of Mechanisms Underlying Metastatic Melanoma Immune Escape via Suppression of Major Histocompatibility Complex (MHC) II through Dysregulation of the JAK/STAT Pathway

  2015cites this paper
• Physiology of Cancer: Prospective Aspects beyond the 21st Century

  2015cites this paper
• Metastatic Melanoma Cells Evade Immune Detection by Silencing STAT1

  2015cites this paper
• Insight into early-phase trials for lung cancer in the United States

  2015cites this paper
• Defining “mutation” and “polymorphism” in the era of personal genomics

  2015cites this paper